Skip to main content

Find Drugs & Conditions

Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.

FDA Approves Myhibbin (mycophenolate mofetil) Oral Suspension for Prophylaxis of Organ Rejection

WOBURN, Mass. May 6, 2024 – Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products...

US FDA Approves High-Concentration, Citrate-Free Formulation of Cyltezo (adalimumab-adbm) injection

Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of...

Planters Peanut Products Under Recall Due to Listeria Risk

Planters peanut products sold at Publix and Dollar Tree in five states are being recalled due to the risk of Listeria contamination, maker Hormel announced.The...

That 'New Car Smell' Could Be Toxic Carcinogens

“New car smell” is a beloved benefit of buying a new vehicle.However, at least part of that scent could be due to toxic carcinogens released by flame...

Gene Discovery Points to a New Form of Alzheimer's

People who carry two copies of the gene mutation most strongly implicated in Alzheimer’s disease are almost certain to develop brain changes related...

Scientists May Have Located Your Brain's 'Neural Compass'

Researchers say they’ve identified a human “neural compass” -- a pattern of brain activity that helps prevent humans from becoming lost.For the first...

Positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

STOCKHOLM, May 6, 2024. Calliditas Therapeutics AB ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its...

Seven Percent of Outpatients Experience One or More Adverse Event

Among outpatients, 7.0 percent have at least one adverse event (AE), with adverse drug events being the most common, according to a study published online...

Racial, Ethnic Disparities Seen for Leading Causes of Youth Mortality

There are racial and ethnic disparities for nearly all leading causes of injury and disease tied to youth mortality, according to a study published online...

Mortality Risk Up for Cancer Survivors With Elevated Loneliness

Cancer survivors with elevated loneliness have a higher mortality risk, according to a study published online April 25 in the Journal of the National Comprehensive...

Doppler Ultrasound Feasible for First-Line Diagnosis of Giant Cell Arteritis

For patients with high clinical suspicion of giant cell arteritis (GCA), color Doppler ultrasound of the temporal artery as a first-line diagnostic tool...

Phase 2 data for Erleada plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer results published

SAN ANTONIO, May 3, 2024. Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment...

When in Life Are Folks Most Lonely?

At what age does loneliness strike adults the hardest? A new review maps it out, finding that people are more lonely as young adults, grow less lonely...

Read more news...

Recently Added

Recently added consumer and prescribing information: Myhibbin, Rezenopy, Libervant, Beqvez, Xolremdi, Pivya, Xromi, Risvan, Voydeya, Winrevair

For Consumers

For Professionals

For Researchers

Latest FDA New Drug Approvals

  • Myhibbin Myhibbin (mycophenolate mofetil) is an antimetabolite immunosuppressant used for the prophylaxis of organ rejection.
  • Libervant Libervant (diazepam) is a buccal film formulation of the benzodiazepine diazepam that may be given to treat children aged 2 to 5 years with...
  • Xolremdi Xolremdi (mavorixafor) is a CXC chemokine receptor 4 (CXCR4) antagonist indicated in patients 12 years of age and older with WHIM syndrome...

More FDA approvals

Drugs in Development (Not yet approved)

  • Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) to...

More drugs in development